Sandbox drugchapter: Difference between revisions

Revision as of 06:50, 10 February 2014

Rizatriptan
MAXALT^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Rizatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

==

Adapted from the FDA Package Insert.

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{XXXXX}}
+{{Rizatriptan}}
 {{CMG}}
-==Title==
+==
+<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = MAXALT (RIZATRIPTAN BENZOATE) TABLET MAXALT-MLT (RIZATRIPTAN BENZOATE) TABLET, ORALLY DISINTEGRATING [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d93286f5-99f7-4dc5-aa9d-ad73ab8490db | publisher =  | date =  | accessdate = }}</ref>
 ==References==
@@ Line 14: / Line 12: @@
 {{FDA}}
-[[Category:Cardiovascular Drugs]]
+[[Category:Antimigraine drugs]]
 [[Category:Drugs]]
+[[Category:Triptans]]